Year Published
- 2008 (0)
- (-) Remove 2009 filter 2009
- 2010 (0)
- 2011 (0)
- 2012 (0)
- 2013 (0)
- 2014 (0)
- 2015 (1) Apply 2015 filter
- 2016 (1) Apply 2016 filter
- (-) Remove 2017 filter 2017
- 2018 (1) Apply 2018 filter
- 2019 (1) Apply 2019 filter
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (2) Apply Countries/Governments filter
- Rural Populations (0)
- Smallholder Farmers (1) Apply Smallholder Farmers filter
- Women (0)
Types of Research
- Data Analysis (1) Apply Data Analysis filter
- Literature Review (3) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (0)
Geography
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (2) Apply South Asia Region and Selected Countries filter
- Southern Africa Region and Selected Countries (3) Apply Southern Africa Region and Selected Countries filter
- Sub-Saharan Africa (4) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (5) Apply West Africa Region and Selected Countries filter
Dataset
- ASTI (1) Apply ASTI filter
- FAOSTAT (2) Apply FAOSTAT filter
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (0)
Current search
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Technology filter Technology
- (-) Remove Political Economy & Governance filter Political Economy & Governance
- (-) Remove 2009 filter 2009
- (-) Remove Global filter Global
- (-) Remove Research & Development filter Research & Development
- (-) Remove 2017 filter 2017
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
Donor countries and multilateral organizations may pursue multiple goals with foreign aid, including supporting low-income country development for strategic/security purposes (national security, regional political stability) and for short-and long-term economic interests (market development and access, local and regional market stability). While the literature on the effectiveness of aid in supporting progress on different indicators of country development is inconclusive, donors are interested in evidence that aid funding is not permanent but rather contributes to a process by which recipient countries develop to a point that they are economically self-sufficient. In this report, we review the literature on measures of country self-sufficiency and descriptive evidence from illustrative case studies to explore conditions associated with transitions toward self-sufficiency in certain contexts.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
The Government of Kenya (GoK) has historically encouraged its farmers to use fertilizer by financing infrastructure and supporting fertilizer markets. From 1974 to 1984, the GoK provided a fertilizer importation monopoly to one firm, the Kenya Farmers Association. However, the GoK saw that this monopoly impeded fertilizer market development by prohibiting competing firms from entering the market and, in the latter half of the 1980s, encouraged other firms to enter the highly regulated fertilizer market. This report examines the state of fertilizer use in Kenya by reviewing and summarizing literature on recent fertilizer price increases, Kenya’s fertilizer usage trends and approaches, market forces, and the impact of government and non-government programs. We find that most studies of Kenya’s fertilizer market find it to be well functioning and generally competitive, and conclude that market reform has stimulated fertilizer use mainly by improving farmers’ access to the input through the expansion of private retail networks. Overall fertilizer consumption in Kenya has increased steadily since 1980, and fertilizer use among smallholders is among the highest in Sub-Saharan Africa. Yet fertilizer consumption is still limited, especially on cereal crops, and in areas where agroecological conditions create greater risks and lower returns to fertilizer use.